Full-length characterization of A1/D intersubtype recombinant genomes from a therapy-induced HIV type 1 controller during acute infection and his noncontrolling partner

AIDS Research and Human Retroviruses

Volumn 24, Issue 3, 2008, Pages 463-472

  Fomsgaard, Anders ^a   Vinner, Lasse ^a   Therrien, Dominic ^a   Jørgensen, Louise B ^a   Nielsen, Claus ^a   Mathiesen, Lars ^b   Pedersen, Court ^c   Corbet, Sylvie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INDINAVIR; LAMIVUDINE; RECOMBINANT DNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ENVELOPE GENE; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CLUSTER ANALYSIS; DENMARK; EPITOPES, T-LYMPHOCYTE; FAMILY HEALTH; FEMALE; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; MALE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHYLOGENY; RECOMBINATION, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; SEROTYPING; UGANDA;

EID: 41449111979     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0294     Document Type: Article

References (46)

1. Migueles SA, Sabbaghian MS, Shupert WL, et al.: HLA-B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term non-progressors. Proc Natl Acad Sci USA 2000;97:2709-2714.
2. Meyer L, Magierowska M, Hubert JB, et al.: Early protective effect of CCR-5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. The SERCO Study Group. AIDS 1997;11:F73-F78.
3. Flores-Villanueva PO, Yunis EJ, Delgado JC, et al.: Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci USA 2001;98:5140-5145.
4. Rodes B, Toro C, Paxinos E, et al.: Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004;18:1109-1116.
5. Lambotte O, Boufassa F, Madec Y, et al.: HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41:1053-1056.
6. Rouzioux C, Hubert JB, Burgard M, et al.: Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ cell counts. J Infect Dis 2005;187:748-757.
7. Trkola A: HIV-host interactions: Vital to the virus and key to its inhibition. Curr Opin Microbiol 2004;7:407-411.
8. Migueles SA, Laborico AC, Shupert WL, et al.: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.
9. Altfeld M, Rosenberg ES, Shankarappa R, et al.: Cellular Immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193:169-180.
10. Kassutto S, Maghsoudi K, Johnston MN, et al.: Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006;42:1024-1031.
11. Garcia F, Plana M, Oriz GM, et al.: The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
12. Davey RT Jr, Bhat N, Yoder C, et al.: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114.
13. Burton CT, Nelson MR, Hay P, Gazzard BG, Gotch FM, and Imami N: Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol 2005;142:354-361.
14. Cohen J: HIV suppressed long after treatment. Science 1997;277:1927.
15. Lisziewicz J and Lori F: Structured treatment interruption in HIV/AIDS therapy. Microbes Infect 2002;4:207-214.
16. Salminen MO, Carr JK, Robertson DL, et al.: Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J Virol 1997;71:2647-2655.
17. Gao F, Robertson DL, Carruthers CD, et al.: A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol 1998;72:5680-5698.
18. Harris ME, Serwadda D, Sewankambo N, et al.: Among 46 near full length HIV type 1 genome sequences from Rakai district, Uganda, subtype D and AD recombinant predominate. AIDS Res Hum Retroviruses 2002;18:1281-1290.
19. Vinner L, Wee EGT, Patel S, et al.: Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 2003;84:203-213.
20. Salminen MO, Koch C, Sanders-Buell E, et al.: Recovery of virtually full length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology 1995;213:80-86.
21. Machuca R, Sch nning K, Hansen J-ES, Bruun L, Fomsgaard A, and Nielsen C: Transmission of a minor variant of transcriptionally active HIV-1. Scand J Infect Dis 1999;31:243-249.
22. Lole KS, Bollinger RC, Paranjape RS, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
23. Corbet SL, Nielsen HV, Vinner L, et al.: Optimization and immune recognition of multiple novel conserved HLA-A02, human immunodeficiency virus type 1-specific CTL epitopes. J Gen Virol 2003;84:2409-2421.
24. Wieland U, Seelhoff A, Hofmann A, et al.: Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. J Gen Virol 1997;78:393-400.
25. Hartley O, Klasse PJ, Sattentau QJ, and Moore JP: V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005;21:171-189.
26. Jensen MA and van't Wout AB: Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003;5:104-112.
27. + T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007;115:757-768.
28. Kim EY, Busch M, Abel K, et al.: Retroviral recombination patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Detlavpx and SIVmac239Deltanef. J Virol 2005;79:4886-4895.
29. Wooley DP, Smith RA, Czajak S, and Desrosiers RC: Direct demonstration of retroviral recombination in a rhesus monkey. J Virol 1997;71:9650-9653.
30. Zhu T, Wang N, Carr A, et al.: Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconverter. J Virol 1995;69:1324-1327.
31. Bernardin F, Herring BL, Peddada L, and Delwart EL: Primary infection of a male plasma donor with divergent HIV variants from the same source followed by rapid fluctuations in their relative frequency and viral recombination. AIDS Res Hum Retroviruses 2003;19:1009-1015.
32. Carr JK, Salminen MO, Albert J, et al.: Full genome sequences of human immunodeficiency virus type 1 subtype G and A/G inter subtypic recombinants. Virology 1998;247:22-31.
33. Delgado E, Thomson MM, Villahermosa ML, et al.: Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Garlicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002;29:536-543.
34. Leitner T, Escanilla D, Marquina S, et al.: Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology 1995;209:136-146.
35. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;2:204-210.
36. Trkola A, Kuster H, Rusert P, et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005;11:615-622.
37. Kaul R, Dong T, Plummer FA, et al.: CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001;107:1303-1310.
38. Rowland-Jones SL, Pinheiro S, Kaul R, et al.: How important is the "quality" of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett 2001;79:15-20.
39. Chouquet C, Autran B, Gomard E, et al.: Correlation between breadth of memory HIV-specific cytotoxic T-cells, viral load and disease progression in HIV infection. AIDS 2002;16:2399-2407.
40. Pantaleo G, Demarest JF, Schacker T, et al.: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-258.
41. Goulder PJ, Phillips RE, Colbert RA, et al.: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
42. Kiepiela P, Ngumbela K, Thobakgale C, et al.: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2006;13:46-53.
43. Goulder PJR, Altfeld MA, Rosenberg ES, et al.: Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001;193:181-193.
44. Grossman Z, Meier-Schallersheim M, Paus WE, and Picker L: Pathogenesis of HIV infection: What the virus spares is as important as what is destroys. Nat Med 2006;12:289-295.
45. Katzenstein T, Dickmeiss E, Aladin H, et al.: Failure to develop HIV infection after receipt of HIV-contaminated blood and post-exposure prophylaxis. Ann Intern Med 2000;133:31-34.
46. Kaufmann DE, Lichterfeld M, Altfeld M, et al.: Limited durability of viral control following treated acute HIV infection. PLoS Med 2004;1(2):e41.